Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)

Daihan Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	57,605	61,302	101,501	90,857	83,765	61,398
Short-Term Investments	14,410	8,934	2,858	6,750	12,650	6,202
Trading Asset Securities	35,000	7,000	-	-	-	-
Cash & Short-Term Investments	107,015	77,237	104,359	97,607	96,415	67,600
Cash Growth	46.12%	-25.99%	6.92%	1.24%	42.63%	25.50%
Accounts Receivable	28,687	31,225	30,857	31,306	29,101	28,947
Other Receivables	1,713	1,347	85.13	932.21	71.32	130.33
Receivables	30,400	32,572	30,942	32,238	29,172	29,077
Inventory	29,836	26,735	23,588	24,939	20,632	23,733
Prepaid Expenses	101.31	82.8	79.94	74.87	107.4	162.26
Other Current Assets	729.73	739.83	935.43	1,026	1,212	1,111
Total Current Assets	168,082	137,366	159,905	155,886	147,539	121,684
Property, Plant & Equipment	136,580	134,441	125,853	113,236	113,831	113,396
Long-Term Investments	26,265	52,175	8,065	7,394	10,129	16,861
Other Intangible Assets	397.01	397.01	397.01	397.01	397.01	397.51
Long-Term Accounts Receivable	-	0	-	0	-	-
Long-Term Deferred Tax Assets	-	-	-	-	398.84	493.64
Other Long-Term Assets	31.71	32.18	33	67.34	247.34	257.34
Total Assets	331,356	324,411	294,252	276,980	272,542	253,090
Accounts Payable	18,908	17,753	17,227	18,104	15,108	15,497
Accrued Expenses	552.01	795.63	777.66	739.86	674.52	639.34
Short-Term Debt	-	-	-	2,500	2,700	3,700
Current Portion of Long-Term Debt	-	-	-	-	6,800	4,000
Current Portion of Leases	31.5	26.27	-	-	16.57	242.41
Current Income Taxes Payable	4,684	4,357	4,466	5,130	5,662	1,124
Other Current Liabilities	21,787	19,712	18,830	16,211	15,158	14,021
Total Current Liabilities	45,963	42,644	41,300	42,686	46,119	39,224
Long-Term Debt	-	-	-	4,000	14,000	20,800
Long-Term Leases	9.05	2.76	-	-	-	16.57
Long-Term Deferred Tax Liabilities	577.17	555	303.87	775.87	-	-
Other Long-Term Liabilities	597.07	589.7	594.63	565.8	506.37	845.57
Total Liabilities	53,008	48,418	46,278	51,582	69,734	71,166
Common Stock	3,000	3,000	3,000	3,000	3,000	3,000
Additional Paid-In Capital	175.92	175.92	175.92	175.92	175.92	175.92
Retained Earnings	268,899	266,545	238,525	216,086	190,078	169,194
Treasury Stock	-3,418	-3,418	-3,418	-3,418	-	-
Comprehensive Income & Other	9,691	9,691	9,691	9,554	9,554	9,554
Shareholders' Equity	278,348	275,994	247,974	225,398	202,808	181,923
Total Liabilities & Equity	331,356	324,411	294,252	276,980	272,542	253,090
Total Debt	40.55	29.03	-	6,500	23,517	28,759
Net Cash (Debt)	106,974	77,208	104,359	91,107	72,899	38,841
Net Cash Growth	46.06%	-26.02%	14.55%	24.98%	87.68%	76.37%
Net Cash Per Share	-	13130.53	17748.21	15223.16	12149.75	6473.51
Filing Date Shares Outstanding	-	5.88	5.88	5.88	6	6
Total Common Shares Outstanding	-	5.88	5.88	5.88	6	6
Working Capital	122,119	94,722	118,604	113,200	101,420	82,460
Book Value Per Share	-	46937.72	42172.46	38333.01	33801.34	30320.57
Tangible Book Value	277,951	275,597	247,577	225,001	202,411	181,526
Tangible Book Value Per Share	-	46870.20	42104.94	38265.49	33735.17	30254.32
Land	59,385	59,385	59,380	56,796	55,727	55,727
Buildings	68,900	68,862	61,781	59,354	49,971	49,420
Machinery	87,774	86,007	81,358	78,438	77,615	77,976
Construction In Progress	20,224	18,158	15,484	3,225	8,857	1,995

Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.